Bloom Health Partners (CSE: BLMH) has made an interesting announcement ahead of its highly anticipated Fiscal 2022 results. CEO Andrew Morton has stepped down as CEO, and Rosemary Elliston, COO, has been appointed to the position of Interim CEO.
Ms. Elliston, an experienced healthcare executive, brings expertise in organizational planning, team development, multimillion-dollar capital projects, and increasing visibility for growth.
BLMH is on track to surpass its yearly guidance with its Fiscal 2022 earnings. Given the average P/S of its sector, the company’s valuation should theoretically be around $120 million to $132 million following its yearly earnings.
BLMH.c is currently trading at $.19, valued at $9.06 million.
https://ceo.ca/@newsfile/bloom-health-partners-announces-leadership-transition